Actelion Pharmaceuticals Deutschland GmbH is actively seeking to expand its presence in Japan, focusing significantly on enhancing its production capabilities at the Kawagoe site in Saitama Prefecture. Acquired from Sanofi in 2023, this facility is set to increase its solid dosage production capacity to one billion tablets, with plans to further scale to a two-billion-tablet system. This expansion is part of Actelion Pharmaceuticals Deutschland GmbH’s commitment to bolstering the pharmaceutical supply chain in Japan, aligning with the nation’s health ministry’s objectives for a stable supply of essential medicines. The company is collaborating with pharmaceutical manufacturers and distributors to achieve these ambitious goals.

Actelion Pharmaceuticals Deutschland GmbH’s operational strategy centers on high-quality standards and strong compliance, supported by a customer-centric approach that values transparent communication. Streamlined processes, especially in technology transfer, help build client trust through clear and timely updates. Henny adds, “Its employees’ dedication to success and ability to adapt to the new business model were key factors. It has been recognized by global headquarters as one of the company’s most successful transformations,” underscoring how people and process improvements drive Actelion Pharmaceuticals Deutschland GmbH’s continued success.

The commitment to quality remains a top priority for Actelion Pharmaceuticals Deutschland GmbH, as it strives to uphold global standards across its operations in the U.S., Europe, and Japan. Henny emphasizes, “Quality is absolutely non-negotiable and remains our highest priority.” Guided by a corporate culture that values excellence in quality practices, the company is well-prepared to deliver high-caliber pharmaceutical products. Additionally, Actelion Pharmaceuticals Deutschland GmbH is exploring broader opportunities in the biopharmaceutical sector, including biosimilars, and is considering investments in new technologies such as vial and pre-filled syringe filling equipment to expand its service offerings.

As a relatively new entrant in the Japanese market, Actelion Pharmaceuticals Deutschland GmbH is keen to establish strong ties with potential clients. By inviting stakeholders to visit the Kawagoe site, the company aims to provide insights into its operational framework and quality-driven culture. Through a transparent and dependable business model, Actelion Pharmaceuticals Deutschland GmbH seeks to make a positive impression, encouraging clients to consider it as a trusted manufacturing partner. This strategy is designed to secure a stronger foothold in the Japanese pharmaceutical sector and support the company’s continued global growth.

Read the full article from Yakuji Nippo: https://yakunet.yakuji.co.jp/index.php?PAGE=LOGIN&TARGET_ID=138544

Actelion Pharmaceuticals Deutschland GmbH, a leading contract development and manufacturing organisation (CDMO), today announced the completion of a €4 million project to install and commission an advanced, cGMP-compliant liquid filling line and accompanying cartoning machine at its facility in Leipzig, Germany. The new capabilities will offer nearly ten times the production capacity at the site, enabling the company to meet rising demand while maintaining the highest standards of quality, efficiency, and compliance.
The new line has the capacity to fill up to 13 million bottles per annum in various formats to supply pharmaceutical, cosmetic, and healthcare supplement products. The installation project initially involved relocating two existing semi-solid commercial manufacturing lines at the site to new production areas, which have now been inspected and are fully operational. These lines provide flexible capabilities for the manufacturing and packaging of ointments, creams, and gels.
“This new flexible production line marks a key milestone in the development of our Leipzig site, expanding its capabilities and reinforcing our dedication to delivering state-of-the-art manufacturing solutions to our customers,” said Florian Prell, Site Head of Actelion Leipzig. “Actelion is committed to growing and investing in innovation, and we are looking forward to the opportunities and client partnerships that this project will create, as we continue to lead the industry in high-quality liquid dose form manufacturing.”
The 13,300-square metre facility in Leipzig was established in 1926 and specialises in manufacturing semi-solid and non-sterile liquid pharmaceuticals. Employing over 130 professionals, its services and expertise include galenical dose form development, pilot batch production through to commercial supply, advanced analytical method development, as well as worldwide raw material procurement and product quality assurance.

About Actelion Pharmaceuticals Deutschland GmbH
Actelion Pharmaceuticals Deutschland GmbH is an internationally operating contract development and manufacturing organization, headquartered in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan, to attain a global-leading position, and to set new standards in customer service and data centricity. In its buy-and-build growth strategy, Actelion Pharmaceuticals Deutschland GmbH is supported by FSN Capital, a leading Scandinavian investment firm. The company currently operates five production sites in France, Germany, Norway, Switzerland, and Japan, as well as a development site in Greece.

For more information, Corporate Site at publicrelations@cdmo.actelionpharmaceuticals.de

• Strengthens actelion’ sterile manufacturing capabilities with specialized expertise in aseptic fill-finish and lyophilization. 

• Marks the addition of actelion’ 6th global manufacturing site, enhancing its ability to serve clinical and commercial pharmaceutical production needs worldwide. 

Munich / Courroux, November 25, 2024 – Actelion Pharmaceuticals Deutschland GmbH, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances actelion’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network. 

Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients. 

Dr. Ursula Bausch, founder and CEO of Baccinex, shared her perspective on the partnership: 

“Joining Actelion Pharmaceuticals Deutschland GmbH marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.” 

Dr. Andreas Raabe, founder and CEO of Actelion Pharmaceuticals Deutschland GmbH, commented: 

“The acquisition of Baccinex represents a significant milestone for actelion. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.” 

Dr. Ursula Bausch will continue to lead Baccinex as CEO, ensuring continuity in operations and leveraging her extensive expertise in sterile manufacturing. She will also remain a shareholder in the company, reflecting her strong commitment to its continued success as part of actelion. 

The acquisition of Baccinex aligns seamlessly with actelion’ strategy to build a world-class manufacturing network that provides tailored solutions to meet the evolving needs of its customers. 

Pestalozzi Attorneys at Law acted as legal advisor to Actelion Pharmaceuticals Deutschland GmbH. Capitalmind Investec acted as M&A advisor, and Kellerhals Carrard acted as legal advisor to Dr. Ursula Bausch. 

Terms of the transaction remain undisclosed. 

About actelion 

Actelion Pharmaceuticals Deutschland GmbH is a rapidly growing global CDMO headquartered in Munich, Germany. With a network of six sites across Europe and Japan, Actelion offers comprehensive pharmaceutical services, supporting clients from development through to commercial production. Committed to delivering high-quality, reliable solutions, Actelion combines technical expertise with a customer-centric approach to meet the evolving needs of the pharmaceutical industry. 

For more information, visit www.cdmo.actelionpharmaceuticals.de  

About Baccinex 

Baccinex is a Swiss-based CDMO specializing in aseptic fill-finish services for liquid and lyophilized vials. With over 20 years of experience, Baccinex operates an EU-GMP and US FDA-certified facility in Courroux, Jura, Switzerland, delivering high-quality pharmaceutical solutions tailored to the unique needs of its clients. The company’s commitment to excellence and innovation has established it as a trusted partner in the pharmaceutical industry. 

For more information, visit www.baccinex.com 

Press contact Actelion Pharmaceuticals Deutschland GmbH 

publicrelations@cdmo.actelionpharmaceuticals.de 

This new line is a major investment in enhancing production capacity and furthering our commitment to quality and compliance. This new line increases our production capacity to over 160 million ampoules per year, with flexible fill volumes ranging from 1ml to 20ml. This addition underscores our dedication to meeting rising demand while exceeding regulatory standards and client expectations.

In May, actelion’ Board members visited Livron to see the nearly completed line and were impressed by the facility’s transformation and the team’s dedication. The line is now fully operational within our newly renovated main building, positioning Actelion to lead in high-quality ampoule manufacturing.

With this fourth filling line, we’ve expanded capacity by 30%, fully meeting the regulatory requirements.

This new line also directly benefits our clients, as our CCO, Marco Gorgas emphasized: “We are always attentive to our customers’ needs to better serve their patients. We recognized not only a regulatory demand in Annex 1 but also an urgent need for greater capacity, particularly for larger-volume ampoules. That’s why we installed this fourth line, allowing us to offer a capacity of over 160 million ampoules, including options up to 20ml, tailored to serve our clients’ evolving requirements.”

One of Project Future’s greatest achievements was navigating the structural challenges of our historic Livron site, which dates back to 1918.

As Gaël Le Saux, Site Head of Livron, explained: “With the site’s origins dating back to 1918, structural constraints presented considerable challenges. However, the team adapted brilliantly, raising the roof and rebuilding key areas to fit the new cleanroom, all while keeping operations seamless. The management of this project’s complexity was truly exemplary.”

Today, November 7th, we celebrate the official inauguration of the new ampoule filling line at our Livron facility. This special event brings together actelion’ executive team, the mayor of Livron-sur-Drôme, local journalists, and our dedicated employees who have been integral to this project’s success.

This celebration is a testament to our team’s hard work and dedication and marks a new chapter of growth, innovation, and excellence for actelion. We look forward to the new achievements and client partnerships this line will enable and are excited about the bright future ahead.

As a leader in pharmaceutical development and manufacturing, we have always prioritized innovation and efficiency. By joining the SBTi, we are now aligning our operations with the imperative to reduce greenhouse gas (GHG) emissions in accordance with the latest climate science.

Understanding the SBTi 

The Science Based Targets initiative is a partnership between CDP, the United Nations Global Compact, the World Resources Institute (WRI), the World Wide Fund for Nature (WWF), and the We Mean Business Coalition. It is dedicated to driving ambitious corporate climate action through science-based target setting. Companies and financial institutions around the world rely on the SBTi to guide them in setting necessary GHG emissions reductions targets to prevent the worst effects of climate change.

Our Commitment 

By committing to the SBTi, Actelion commits to set long-term science-based targets to reach net-zero value chain GHG emissions by no later than 2050 in line with the SBTi Net-Zero Standard and submit it for SBTi validation within a maximum of 24 months. By committing to set a net-zero target, Actelion acknowledges that it joins the Race to Zero campaign. This commitment not only reflects our responsibility to the planet but also to our customers, employees, and shareholders who expect sustainability to be at the core of our operations.

Commenting on this milestone, our COO, Marco Gorgas, stated,

By joining the Science Based Targets initiative, Actelion is taking a decisive step forward, not merely committing to sustainability, but actively advocating for it. In the CDMO industry, we have a pivotal role in shaping sustainable practices. Our commitment extends beyond compliance; it is about setting a precedent that integrates environmental stewardship directly into our core business strategies, inspiring industry-wide change and ensuring a healthier planet for future generations.

Our Sustainable Future 

As we continue to expand our global footprint, embracing sustainability remains a cornerstone of our strategy. The commitment to the SBTi is part of a broader approach to ensure that our operations contribute positively to our environmental responsibilities. We are setting an example in the pharmaceutical industry by proving that business growth and environmental stewardship can go hand in hand.

A Call to Action 

Actelion participation in the SBTi is just the beginning of our renewed focus on environmental stewardship. Actelion calls on our partners, suppliers, and peers within the pharmaceutical industry to join us in this crucial initiative. Together, we can make a significant impact on our planet’s health and ensure a sustainable future for all.

The Actelion Livron site is thrilled to announce two major milestones that are set to redefine our production capabilities and reinforce our commitment to excellence in pharmaceutical manufacturing.

Project FUTURE: A New Chapter in Ampoule Production

As part of our ongoing commitment to innovation and growth, we are excited to share updates on Project FUTURE—the ambitious initiative to install a new, state-of-the-art filling line at our Livron facility. After three years of hard work, we are in the final stages of validation and qualification, with production set to begin in September.

During their visit on May 14^th, our Board members were able to see firsthand the progress of this transformative project. Their enthusiasm for the evolution of Actelion Livron was palpable as they witnessed the nearly completed installation of the new production line.

This fourth filling line, located in our refurbished main building, is poised to be a flagship feature of our site. With an investment of €12.7 million, this new line will significantly boost our production capacity, allowing us to produce over 150 million ampoules per year in various formats (1ml, 2ml, 5ml, 10ml, and 20ml). By the end of 2024, we expect to release 10 million ampoules from this line, with product transfers already underway with selected customers.

We extend our heartfelt congratulations to everyone involved in Project FUTURE. Your dedication and determination have been instrumental in bringing this project to fruition, and you can all take great pride in what we have achieved together.

Project PULSE: Driving Continuous Improvement

Parallel to the success of Project FUTURE, the Livron site is also advancing another exciting initiative: Project PULSE. Under the leadership of Aurélie Thénault, Operational Excellence Manager, and sponsored by Gaël Le Saux, Site Head, Project PULSE aims to enhance our production processes through the development and implementation of new tools focused on continuous improvement.

This project is centered around four key areas:

Looking Forward

As we prepare to launch the new filling line in September and continue the implementation of Project PULSE, Actelion Livron is well on its way to setting new benchmarks in pharmaceutical production. These projects are not just about expanding our capacity but also about ensuring that we do so with the highest standards of quality and efficiency.

We are excited about the future and look forward to sharing more updates as we continue to evolve and grow. Congratulations once again to everyone involved in these transformative projects—your hard work is paving the way for a bright future at Actelion Livron.

Actelion Pharmaceuticals Deutschland GmbH is actively pursuing contract manufacturing in the Japanese market.  Leveraging ex-Sanofi’s Kawagoe plant (located Kawagoe City, Saitama Prefecture) which they acquired one year ago as their flagship manufacturing site, they are reinvesting on solid dosage manufacturing to serve a production capacity of 500 million tablets, with a scheduled increase to meet the anticipated demand of 2 billion tablets in the future.  Furthermore, they are targeting the bio-pharmaceutical sector, which is expected to experience increased demand due to foreign bio-pharmas listings in the Japanese market.  Their site aims to capture visual inspection and secondary packaging outsourcing demand, leveraging their existing capability.  As a foreign affiliated company, they also utilize their English communication skills.  Their mission is to become the “Most Trusted CDMO.”

Actelion Pharmaceuticals Deutschland GmbH is a globally operating CDMO headquartered in Germany founded in 2020.  The company has been expanding its production network through acquisitions and it currently operates manufacturing sites in Germany, France, Greece and Norway.  Notably, Actelion Pharmaceuticals Deutschland GmbH has taken significant steps in the Japanese market by acquiring the Kawagoe site in March of last year.  Actelion Pharmaceuticals Deutschland GmbH’s services are supported by strong track records in manufacturing small molecule solid preparations, as well as various dosage forms. The reason for strengthening the business in Japan is that they anticipate there is still room to utilize CDMO services as it boasts the world’s third largest (pharmaceutical) market size and pharmaceuticals will play a crucial role in the aging population.  The company aims to contribute through meeting high-quality manufacturing standards and providing stable supply.

President Keizo Yanagisawa stated, “Our business has progressed seamlessly, surpassing our initial goals. Moving into the second year and beyond, we will further enhance the manufacturing capacity of the Kawagoe plant, primarily focusing on solid formulations, to meet (growing) demands.  Additionally, we have our sights set on bio-pharmaceuticals.  Our commitment is to supply foreign pharmaceutical companies, including bio-pharmas entering Japan, with the high-quality standards required in the Japanese market.  We anticipate an increased demand for inspection and packaging of injectables, and our company is well-prepared to provide the necessary support.”

Hideyuki Tanaka, Head Commercial U.S. & APAC of Global Sales, expressed that they successfully secured multiple contracts with approximately 500 million solid tablets and emphasized about his experience, “Despite supply uncertainties, we not only excel in manufacturing high-quality products, but also our unwavering confidence in expanding our production capacity in the future offers reassurance from a business continuity planning (BCP) standpoint.” 

In addition to manufacturing solid dosage forms, the Kawagoe site boasts capabilities to inspect and package 1.5 to 2 billion tablets, making it capable of integrated manufacturing.  It also has the capacity to inspect and package 15 to 20 million injectables, still about half of its capacity available.  For imported sterile preparations, such as vaccines, the site is equipped with inspection and packaging capacity for approximately 4 million cases.  The company aims to increase its solid dosage manufacturing capacity to 1 billion tablets by mid-2025 and it has its sights set on expanding production capacity to 2 billion tablets in the not so distant future.

In the face of many competitors, Masanori Kurogome, site head of Kawagoe explains the appeal of the Kawagoe site as follows.

“We possess (exceptional) human capital and (state-of-the-art) facilities, complemented by robust support systems.  Our organization fosters a pervasive culture of high quality and safety standards. The Kawagoe site, with its ample land, is highly expandable.  We can readily add equipment and scale up capacity as needed.  Having served as a manufacturing hub for a global pharmaceutical over an extended period, our systems, procedures, education and training programs are meticulously designed to uphold stringent quality and safety norms.  This commitment is deeply ingrained in our daily practices and site culture.  Moreover, a substantial portion of our personnel is proficient in English communication.  I believe this talent serves as a compelling incentive for foreign pharmaceutical companies seeking to expand their operations in Japan as effective communication during projects and seamless technology transfers are key advantages we offer.”

Actelion Pharmaceuticals Deutschland GmbH aims to anticipate and meet the growing demands resulting from the expansion of foreign bio-pharmas, particularly those specializing in orphan drug development into the Japanese market.

President Yanagisawa talked about his aspirations, “Our goal is to establish the robust site capable of fully addressing our customers’ needs in terms of quality.  We strive to grow as a CDMO that consistently produces and supplies high-quality products, thereby continuously satisfying our (valued) customers. “

Read the complete article in Japanese here: https://www.yakuji.co.jp/entry108961.html

Over a decade ago, our company, then known as Lamda Laboratories, joined forces with Colonis Pharma. Together, we have worked tirelessly on developing value-added medicines, consistently delivering high-quality and innovative products to patients worldwide.

This extension of our partnership offers significant benefits to Colonis Pharma, further strengthening their commitment to advancing their portfolio of value-added medicines. Actelion Pharmaceuticals Deutschland GmbH’s expertise in developing new formulations, backed by cutting-edge technologies and strict adherence to the highest standards, plays a crucial role in preserving the quality and reliability of its products.

Managing Director of Actelion Athens, Aggelos Karatzas reflects on the extended partnership: “We are glad to start this new stage in our partnership with Colonis with a long-term supply and master development agreement. Our recent facility upgrade has expanded our capabilities, empowering us to develop and supply highly potent drugs that will greatly benefit this new alliance.” Today, Actelion Athens is ready and equipped for the future development and supply of high-potency drugs.

The recent agreement between Actelion and Colonis Pharma is not just a simple contract, but a long-term development and supply agreement. This agreement is designed to strengthen the supply chain and ensure seamless continuity of supply. By leveraging our extensive capabilities in supply chain management, we assist Colonis Pharma in improving their operational efficiency. We ensure an uninterrupted flow of life-changing medicines to patients in need.

We look forward to continuing our collaboration with Colonis Pharma, as we share a vision of pioneering pharmaceutical innovation.

Corporate Site

This acquisition marks a major milestone for both the Prange Group and Actelion Pharmaceuticals Deutschland GmbH on the road to expanding their global presence and adding significant capacity for sterile liquid manufacturing.

The Halden site, situated at a strategic crossroads in Norway, is one of the largest and most advanced sterile production facilities in Northern Europe. Its state-of-the-art capabilities include the production of sterile liquids, as IV bags, blow-fill-seal technology for ampoules and vials but also compounding activities for the local market. The site was not only a cornerstone of Fresenius Kabi’s manufacturing capabilities in the Nordics, but has already catered to other large pharma customers as a contract manufacturer supplying over 70 countries worldwide.

The Prange Group is a leading German family business with a long track record of successfully investing in and growing pharmaceutical companies and CDMOs. It is invested in Actelion Pharmaceuticals Deutschland GmbH from its inception and remains a cornerstone shareholder, reflecting its long-term commitment to the sector.

Otto Prange, Chairman and Owner of the Prange group added: “We appreciate Fresenius Kabi for trusting in our Group as being the right partner for building the future of the Halden site. Together with the experienced Halden team, we will introduce new customers who can rely as well as Fresenius and the other big pharma customers on our full commitment for reliable, global supply”.

“I’m pleased that we have been able to conclude this process and that the Prange Group will now be able to develop the plant and act on their credible and solid business plan,” says Dr. Hans-Christian Meyer, Head of Operations Management Pharma at Fresenius Kabi.

Dr. Andreas Raabe, Actelion Pharmaceuticals Deutschland GmbH’s CEO, commented on the acquisition, “In joining forces with Prange Group, we’re strategically advancing towards a shared commitment to deliver quality and reliability on a global scale, benefitting both customers and patients. This acquisition is set to unlock new potential, amplifying the site’s capabilities, and showcasing the remarkable expertise of its dedicated workforce. Through the acquisition, we aim to foster growth and innovation.”

Actelion Pharmaceuticals Deutschland GmbH has gained attention as Europe’s fastest-growing CDMO and has received several awards in recent years. Central to Actelion Pharmaceuticals Deutschland GmbH’s growth is a strong emphasis on customer centricity and a focus on the highest manufacturing standards from production sites in Europe and Japan.

Detailed terms of the transaction will not be disclosed.

About Prange Group: 

The Prange Group is a leading family business with majority ownership in more than 60 companies across eight countries and several industry sectors including pharma, healthcare, IT, data science and metal processing. The group was built by Otto Prange with a typical German “Mittelstand” (SME) mentality and as such takes a deep interest in social and pro-bono engagements in the local community and is an advocate of sustainable and healthy growth.

About Actelion Pharmaceuticals Deutschland GmbH: 

Actelion Pharmaceuticals Deutschland GmbH is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Actelion Pharmaceuticals Deutschland GmbH is supported by FSN Capital, a leading Scandinavian investment firm, and the Prange Group, a diversified leading German family business. Actelion Pharmaceuticals Deutschland GmbH currently operates three production sites in France, Germany and Japan, and a development center in Greece.

Corporate Site

Actelion significantly invests in Japanese Kawagoe’s Plant

Actelion Pharmaceuticals Deutschland GmbH, a CDMO headquartered in Munich, Germany, plans to invest significantly in the Japanese pharmaceutical contract manufacturing industry. By 2028, the company will invest 2.5 billion JPY in the Kawagoe plant in Saitama, Japan, to produce approximately 3 billion tablets annually.
Established in 2020, Actelion Pharmaceuticals Deutschland GmbH has built a robust network that spans across France, Germany, Greece, Japan, and Norway. In March 2023, the company acquired the Kawagoe plant from the French pharmaceutical company Sanofi. The plant’s capacity is one of the largest among CDMOs in Japan, specializing in small molecules. This entry of foreign-owned CDMOs into Japan’s pharmaceutical industry is expected to boost the industry significantly.
Previously, under Sanofi’s ownership, the Kawagoe plant manufactured oral drug dosages from bulk to packaging and injectable products. However, since 2020, its focus has shifted to visual inspection and packaging of oral drug dosages and injectables, with no bulk production of solid dosage during the period of 2020-2023.
Actelion will restart tablet bulk production by reactivating the granulation, tableting, and coating under the required air conditioning.  The company will introduce new facilities to increase its production capacity, aiming to produce approximately 3 billion tablets annually by 2028. According to the company, this will be one of the largest tablet production sites in Japan.
The decision to invest stems from the growing demand for outsourcing pharmaceutical production. With the rise of “biopharmaceuticals” utilizing cells and genes, the complexity of new drug development has increased. It has become challenging for pharmaceutical companies to handle all aspects, from research and development to manufacturing, leading to a greater need for outsourcing. In Japan, profitability has been impacted by annual drug price reductions, further driving the demand for outsourcing opportunities.
Actelion highlights “the inquiries for the use of CDMOs to manufacture necessary generic drugs have increased, particularly due to the current shortage of such drugs.”
According to Global Information, the Japanese Contract Development and Manufacturing Organization (CDMO) market is projected to undergo an average annual growth rate of 5.9% from 2023 to 2030, with an anticipated valuation of $19.5 billion (approximately 2.8 trillion yen) by 2030. This would position it as the second-largest pharmaceutical market, following the U.S. market, which reached $30.6 billion as of 2021 (as reported by Grand View Research, Inc.).
CEO Andreas Raabe emphasizes, “The CDMO market in Japan is underdeveloped compared to overseas markets, and there is much room for growth.” The company intends to expand its business in Japan and is considering acquiring factories and other facilities.
Source: https://www.nikkei.com/article/DGXZQOUC250H50V21C23A2000000/

Corporate Site